Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594904 | 1.00 | TSHR (0.48) | TSHRNAAACA1CA2CA7 | |
| SCHEMBL17697791 | 0.98 | TSHR (0.50) | TSHRNAAACA1CA2CA7 | |
| SCHEMBL30147423 | 0.95 | TSHR (0.44) | TSHRNAAACA1CA2CA7 | |
| SCHEMBL30379634 | 0.95 | TSHR (0.44) | TSHRNAAACA1CA2CA7 | |
| SCHEMBL31411104 | 0.86 | L3MBTL1 (0.51) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10771878 | 0.86 | TDP1 (0.38) | CA1CA2CA9TDP1 | |
| SCHEMBL21068706 | 0.84 | TSHR (0.47) | TSHRNAAACA1CA2CA7 | |
| SCHEMBL21068709 | 0.84 | TSHR (0.47) | TSHRNAAACA1CA2CA7 | |
| SCHEMBL21068961 | 0.84 | TSHR (0.47) | TSHRNAAACA1CA2CA7 | |
| SCHEMBL7863823 | 0.83 | TSHR (0.54) | TSHRNAAACA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| CN-116194084-A | Cleavable lipid compounds, compositions containing the same and uses thereof | 赛诺菲巴斯德有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116134020-A | Lipid compounds comprising at least one terminal group of formula-NH-CX-A or-NH-CX-NH-A, compositions containing them and uses thereof | 赛诺菲巴斯德有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11639354-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3831811-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020027225-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | TSHR 4767/4885NAAA 3990/4885CA1 2393/4885 |
| US-11639354-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | TSHR 4767/4885NAAA 3990/4885CA1 2393/4885 |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | TSHR 4767/4885NAAA 3990/4885CA1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.